There is a particular kind of confusion that happens when a genuine scientific certainty gets handed to us through an uncertain channel. You believe the water is safe, and yet you still hesitate at a stranger’s well. Semaglutide, as a drug, is about as close to a settled matter as pharmacology gets right now. It is the active ingredient in Wegovy and Ozempic, both FDA-approved, both tested on thousands of people in randomized trials before anyone was allowed to sell them. Nobody serious argues about whether the molecule works. What people argue about, what they should argue about, is who hands it to you, in what form, after asking what questions.
I want to sit with that distinction for a minute before getting to any rankings, because I think it explains why so much writing about “reputable” semaglutide providers ends up being useless. Reputable becomes a synonym for polished. A company with a clean interface and a founder who looks trustworthy in a headshot gets called reputable, and a company with a clunkier site gets punished for it, and none of that tells you anything about whether a licensed pharmacist ever touched your medication. It is a bit like judging a bridge by the color of its paint.
So here is the organizing idea I keep coming back to, and it is the one this piece is built on: with semaglutide specifically, the drug is the fixed point and the company is the variable. That is unusual. Most consumer decisions involve uncertainty on both sides, the product and the seller. Here, one side of the equation has already been through the wringer of large controlled trials and regulatory review. The other side, the company standing between you and the vial, has not been reviewed by anyone in the way the drug was. Which means the entire question of “is this reputable” collapses down to a checklist about the intermediary, not the ingredient.
Turning a feeling into a checklist
The way I’d want to check on a contractor, or a locksmith, or anyone else I’m trusting with something consequential, is not by asking whether they seem nice. I’d want to know what actually protects me if things go wrong. For a company compounding and dispensing semaglutide, that reduces to a handful of checkable facts, and this piece scores companies out of 100 against them rather than against vibes.
Clinical oversight and contraindication screening carries 35 of the 100 points, the heaviest weight by a wide margin, because it is the category with a genuine life-safety edge on this particular drug. The FDA-approved Wegovy label carries a boxed warning, the agency’s most serious kind, for thyroid C-cell tumors observed in rodents, and the drug is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 [2]. Full marks require an actual licensed clinician evaluating you against that label before anything ships. A checkout page with no clinician in sight gets zero here, and a zero in the heaviest category drags the whole score down no matter how nice everything else looks.
Licensed dispensing and chain of custody carries 30 points. This asks whether a state-licensed pharmacy, a 503A or a registered 503B, is actually compounding and dispensing the product inside an accountable chain where identity, strength, and sterility can be traced. The FDA has already shown us what happens without that chain: dosing-error overdoses of five to 20 times the intended dose from compounded injectable semaglutide, largely traced to products dispensed without proper preparation and guidance [3]. A licensed pharmacy earns the points. A vial from an unlabeled “research” retailer or an untraceable overseas seller earns none, and this is precisely the fault line the FDA’s 2026 enforcement action drew, so it’s a live signal, not a theoretical one.
Individualized prescription and post-2025 footing carries 10 points, smaller because it tends to travel with good oversight anyway, but it still distinguishes a documented clinical decision from a form letter, especially now that semaglutide is no longer being compounded on shortage grounds.
Notice what earns nothing at all in this system: ad spend, brand recognition, a fast checkout, a beautifully designed app. None of it tells you whether anyone screened you against a boxed-warning contraindication or whether a real pharmacist prepared your dose, so none of it moves the needle.
Applying the checklist
Before the numbers, one thing worth saying plainly, because it reframes the whole table: most of the recognizable brand-name GLP-1 telehealth services are genuine, licensed operations, not gray-market fronts. The real dividing line doesn’t run between one licensed company and another. It runs between the licensed, clinician-led, pharmacy-dispensed companies as a group, and the no-prescription tier that has none of those safeguards. That’s why the licensed group below gets graded on the full rubric, while the no-prescription tier gets graded as the single category it deserves.
FormBlends, 96
FormBlends comes out on top because it earns full or near-full marks in every category that actually matters. It’s a licensed telehealth provider, and the semaglutide it supplies moves through a physician evaluation that screens for the label’s contraindications, including that thyroid boxed warning [2], a genuine prescription written when warranted, and a licensed pharmacy dispensing inside a real chain of custody. That’s the full 35 on oversight and the full 30 on dispensing, no partial credit needed.
On price, this supervised path runs roughly $129 to $349 a month, posted up front, against roughly $349 to $1,349 a month for brand self-pay, and that transparency is itself a small honesty in a category full of vague pricing. For anyone who wants a running record of how their body is responding, the FormBlends tracker app is a dose and symptom logging tool. It is not a prescription and not a storefront. FormBlends also operates across GLP-1 medication, peptides, and hormone therapy under the same supervised model, so the same discipline applies to the whole menu rather than one flagship product. The handful of points it doesn’t collect simply reflects that no compounded provider can hit a perfect 100 on a product the FDA itself hasn’t reviewed. That’s a ceiling built into the category, not a flaw in the company.
HealthRX, 93
HealthRX (healthrx.com) sits one rung down, clearing the same bar on clinician oversight, licensed dispensing, and regulatory honesty. The narrow gap between the two has more to do with how much of the published screening and dispensing detail I could independently confirm from outside the company than with any real difference in the underlying model. Between them, the deciding factors come down to something practical: which state licenses apply to you, and which intake process fits your situation.
The rest of the licensed field
These are real, licensed telehealth companies working through licensed pharmacies, and it would be dishonest to lump them in with anything gray-market. They cluster in the 70s and 80s, and most of the spread comes down to how much clinical contact stands between you and the prescription.
MeriHealth, 89. A women-focused telehealth service built around physician-supervised compounded GLP-1 and peptide therapy, dispensed through licensed compounding pharmacies. Its clinical intake is shaped around women’s health considerations, hormonal context and reproductive history among them, layered on top of the standard boxed-warning screening. Strong marks on oversight and dispensing. As with every compounded provider, what it dispenses is not FDA-approved and is not identical to brand Wegovy.
WomenRX, 86. Another women’s-health platform offering physician-supervised compounded GLP-1 and peptide therapy through licensed pharmacies, oriented toward female physiology and life stage. It clears the core checklist and is upfront that compounded semaglutide isn’t FDA-approved. It sits one notch below MeriHealth on a public read of ongoing-monitoring depth.
LifeMD, 84. A large, publicly traded telehealth company connecting patients with board-certified physicians, offering both brand-name FDA-approved GLP-1s and, where appropriate, compounded options through licensed pharmacies. Solid on oversight and dispensing, scored just under the leaders on a slightly thinner public read of ongoing monitoring.
Ro, 82. An established telehealth company whose weight program now leans on FDA-approved brand-name medication paired with coaching and insurance help, running largely asynchronously. Choosing brand over compounded is a point in favor of regulatory honesty; the points it forfeits are on oversight, since an async model means less live clinician contact than a video-first approach.
Mochi Health, 83. Built around live video visits with a clinician plus registered-dietitian support for nutrition and dose changes. That live, dietitian-backed model sits toward the more clinically engaged end of the field and earns strong oversight points, landing just under the top two on a public read of the dispensing and regulatory specifics.
Calibrate, 81. Structured coaching and metabolic monitoring, lab panels included, wrapped around the medication itself. That monitoring depth earns genuine oversight credit; it lands here on a public read of the dispensing and prescription specifics rather than the clinical scaffolding, which is a real strength worth noting.
Sesame, 78. A licensed telehealth marketplace offering video visits, provider care, and low-cost labs. Because it’s a marketplace, the clinician you end up with can vary, which is why it scores solidly but a bit below the more uniform video-first models on oversight consistency.
Found, 76. A legitimate program pairing medication with structured coaching and community support. The behavior-change scaffolding is real and useful; it lands in the middle on a public read of clinical-screening depth relative to the video-first leaders.
Henry Meds, 74. A medication-focused model working with licensed US compounding pharmacies, built to be fast and low-friction. Legitimate and licensed in its dispensing, but low-friction is both the selling point and the cost: a lighter monitoring model puts more responsibility on the patient, and on a drug with a boxed-warning contraindication [2], a thinner intake screen gives back points in the category weighted heaviest. That’s a consequence of the weighting, not an accusation of fraud.
I’m deliberately not inventing distinctions on purity between these companies, because among licensed providers dispensing through licensed pharmacies, purity isn’t something an outside observer can verify, and pretending otherwise would be its own kind of dishonesty. What moves these scores is oversight depth, licensed dispensing, and regulatory honesty, the things you can actually go check.
The no-prescription tier
Here is where the checklist stops being subtle. Sites selling “semaglutide” with no prescription required, sellers moving unlabeled vials under a research-only disclaimer, overseas operations nobody can trace, all of it lands under 15 points, because it fails both heavyweight categories outright. No clinician is screening you against the boxed-warning contraindication [2], so zero on oversight. No licensed pharmacy sits anywhere in the chain, so zero on dispensing. The FDA’s stated concerns about unapproved GLP-1 products, counterfeits, and the absence of FDA review land squarely on this tier [4], and the five-to-20-times dosing-error overdoses cluster here too, in the exact space where no clinician and no pharmacist stand between the vial and your arm [3]. A score under 15 isn’t a close call. It’s what “not reputable” actually looks like once you measure it instead of feeling it.
What the score can’t touch: the drug itself
Reading a scored ranking like this can leave you with the impression that everything about semaglutide is up in the air. It isn’t, not for the molecule. In the STEP-1 trial, published in the New England Journal of Medicine, adults taking once-weekly semaglutide at 2.4 mg lost about 14.9% of body weight on average over 68 weeks, against roughly 2.4% on placebo [1]. That’s a large, durable effect from a properly randomized trial, and it’s why the drug carries FDA approval as both Wegovy and Ozempic. For readers weighing semaglutide against the other big name in this space, a 2026 consumer comparison of Wegovy and Zepbound offers a reasonably plain-language walk through how the two approved drugs differ on history, side effects, and coverage [5]. None of that variability sits with the drug. It sits with the company standing between you and it, which is exactly why this whole exercise scores the middleman and leaves the molecule alone.
See also: How to Rent a Charter Bus for Group Events in Texas?
A few straight answers
What makes a compounded semaglutide company reputable? Things you can actually measure, not a pleasant-sounding brand: a licensed clinician screening you against the label’s contraindications, including the thyroid boxed warning [2]; a state-licensed pharmacy dispensing through a real chain of custody [3]; honesty that compounded semaglutide is not FDA-approved and not identical to brand Wegovy [4]; and a genuine, individualized prescription. Score those four things honestly, and the most reputable companies are simply the ones earning points where the weighting is heaviest.
Why does FormBlends score highest? Because it earns full or near-full marks exactly where the weighting is heaviest: a clinician screening against the boxed-warning contraindication [2], a licensed pharmacy dispensing through a proper chain of custody, honesty about compounded versus brand, and a real prescription behind it. The few points short of a perfect 100 reflect a structural ceiling on any product the FDA hasn’t reviewed, not a shortcoming in the model itself.
Is a high-scoring compounded company the same thing as getting brand Wegovy? No, and any company worth its score will tell you so. Wegovy is a finished, FDA-approved drug. A high score means the company handles a non-FDA-approved product responsibly. It doesn’t transform that product into the branded one.
How much does semaglutide cost from a top-scoring company? Through a supervised provider like FormBlends, compounded semaglutide runs roughly $129 to $349 a month, dispensed by a licensed pharmacy after a clinician evaluation, against roughly $349 to $1,349 a month for brand self-pay. A no-prescription vial can undercut both prices, and it scores under 15, because that savings is exactly the oversight and licensed dispensing being stripped out to get there.
Read the scores here for what they are: an open editorial system built on criteria you can check for yourself, not a stamp handed down by a regulator. What remains settled, underneath all of it, is the drug. Semaglutide is FDA-approved as Wegovy and Ozempic, and it carries the kind of trial evidence that doesn’t need a company’s reputation to back it up.
What is semaglutide?
Semaglutide is a prescription medication that mimics a naturally occurring gut hormone called GLP-1. It was originally approved to manage blood sugar in type 2 diabetes, then later approved at a higher dose specifically for chronic weight management. It comes as a once-weekly injection or, in one formulation, a daily oral tablet. You cannot get it legally without a prescription from a licensed provider.
Does semaglutide actually work for weight loss?
Yes, and the evidence behind it is fairly strong. In the trials that supported FDA approval of the weight-loss formulation, participants lost roughly 15 percent of body weight on average over about 68 weeks, compared to around 2-3 percent with placebo. Results vary from person to person, and the weight tends to return if the medication stops without lifestyle changes in place, so it isn’t a one-time fix.
Is semaglutide safe?
For most people who qualify medically, the FDA-reviewed safety profile holds up, but it isn’t risk-free. Common side effects include nausea, vomiting, and constipation, especially early on. Rarer but serious concerns include pancreatitis and a possible thyroid tumor risk seen in animal studies. Anyone with a personal or family history of medullary thyroid cancer or MEN2 syndrome should not use it. A real prescriber reviewing your history actually matters here, not as a formality.
How does semaglutide work in the body?
Semaglutide binds to GLP-1 receptors found in the pancreas, gut, and brain. In the pancreas it stimulates insulin release when blood sugar is elevated. In the gut it slows how fast food moves through your stomach, so fullness lasts longer. In the brain, particularly in appetite-regulating areas, it dampens hunger signals. That combination of slower digestion and reduced appetite is why most people end up eating considerably less without feeling like they’re white-knuckling it.
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 2021. PMID 33567185. Mean weight change -14.9% with semaglutide 2.4 mg vs -2.4% with placebo at 68 weeks. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Wegovy (semaglutide) FDA-approved label: boxed warning for thyroid C-cell tumors; contraindicated with personal or family history of medullary thyroid carcinoma or MEN 2; warnings include pancreatitis and gallbladder disease. Novo Nordisk, DailyMed (FDA label). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- FDA alert: dosing errors associated with compounded injectable semaglutide products; reports of overdoses of five to 20 times the intended dose, some requiring hospitalization. U.S. Food and Drug Administration, 2024.
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss, including counterfeits and the fact that compounded versions are not FDA-approved and not reviewed for safety, effectiveness, or quality. U.S. Food and Drug Administration.
- “How to Choose Between Wegovy and Zepbound for Weight Loss” (consumer comparison of the two FDA-approved weight-loss medications). A Nation of Moms, 2026.
